Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

Take The A Train To Ukraine

Kiev, Ukraine

algernonpharmaceuticals.com/wp-content/uploads/2018/01/Algernon-Investors-Deck-Prospectus-Final-August-7-LR.pdf

IBD TRIAL

NP-178

Phase II Design Summary – Low Cost Trial to
Provide Proof of Concept Data for Partnering

• 20 patients with active UC
• 15 weeks
• Open-label
• Primary Endpoint: #pts with 50% reduction in ulcer
area and/or reduction of ES by 1 pt
• Secondary Endpoint: #pts with remission, % reduction
in ulcer area, Geboes index change,
• Country: Australia or Ukraine
• Cost: CDN$1.2M

CKD TRIAL

NP-135

Phase II Design Summary – Low Cost Trial to Provide
Proof of Concept Data for Partnering

• 60 patients
• 16 weeks
• 1:1 Placebo to active
• Primary Endpoint: GFR
• Secondary Endpoint: albuminuria
• Country: Australia or Ukraine
• Cost: CDN$1.2M

Intend to file for Orphan drug status in FSGS for NP-135
• Phase III <120 patients
• Estimated $2B market

NASH TRIAL
NP-135

Phase II Design Summary – Low Cost Trial to Provide Proof
of Concept Data for Partnering

• 50 patients
• 6 months of treatment
• 1:1 Placebo to Active
• Primary Endpoint: Enhanced Liver Fibrosis (ELF) Panel
• Secondary Endpoint: Fibroscan for fibrosis and steatosis, proC3
• Country: Australia (difficult), NZ, HK or Ukraine
• Cost ~ CDN$1.5M (includes cGMP synthesis)

/////AMG